Incretin-based therapies have provided additional options for the treatment of type 2 diabetes mellitus. The aim of our study was to evaluate the effects of exenatide compared to glibenclamide on body weight, glycemic control, β-cell function, insulin resistance, and inflammatory state in patients with diabetes.
Methods:
One hundred twenty-eight patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin were randomized to take exenatide 5 μg twice a day or glibenclamide 2.5 mg three times a day and titrated to exenatide 10 μg twice a day or glibenclamide 5 mg three times a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance (HOMA-IR) index, homeostasis model assessment β-cell function (HOMA-β) index, plasma proinsulin (PPr), PPr/FPI ratio, resistin, retinol binding protein-4 (RBP-4), and high-sensitivity C-reactive protein (Hs-CRP) at baseline and after 3, 6, 9, and 12 months.
Results:
Body weight and BMI decreased with exenatide and increased with glibenclamide. A similar improvement of HbA1c, FPG, and PPG was obtained in both groups, whereas FPI decreased with exenatide and increased with glibenclamide. The HOMA-IR index decreased and the HOMA-β index increased with exenatide but not with glibenclamide. A decrease of PPr was reported in both groups, but only glibenclamide decreased the PPr/FPI ratio. Resistin and RBP-4 decreased with exenatide and increased with glibenclamide. A decrease of Hs-CRP was obtained with exenatide, whereas no variations were observed with glibenclamide.
Conclusions:
Both exenatide and glibenclamide gave a similar improvement of glycemic control, but only exenatide gave improvements of insulin resistance and β-cell function, giving also a decrease of body weight and of inflammatory state.
Get full access to this article
View all access options for this article.
References
1.
HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
2.
TourrelC, BailbéD, MeileMJ, KergoatM, PorthaB. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 2001; 50:1562–1570.
3.
HuiH, NourparvarA, ZhaoX, PerfettiR. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology, 2003; 144:1444–1455.
4.
PerfettiR, ZhouJ, DoyleME, EganJM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 2000; 141:4600–4605.
5.
Toft-NielsenMB, DamholtMB, MadsbadS, HilstedLM, HughesTE, MichelsenBK, HolstJJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 2001; 86:3717–3723.
6.
DeaconCF, JohnsenAH, HolstJJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 1995; 80:952–957.
7.
TriplittCL. New technologies and therapies in the management of diabetes. Am J Manag Care, 2007; 13,Suppl 2:547–554.
8.
Joint Formulary Committee: British National Formulary57th. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
DeFronzoRA, RatnerRE, HanJ, KimDD, FinemanMS, BaronAD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 2005; 28:1092–1100.
11.
BuseJB, HenryRR, HanJ, KimDD, FinemanMS, BaronAD. Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004; 27:2628–2635.
12.
KendallDM, RiddleMC, RosenstockJ, ZhuangD, KimDD, FinemanMS, BaronAD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 2005; 28:1083–1091.
13.
ZinmanB, HoogwerfBJ, DuránGarcía S, MiltonDR, GiaconiaJM, KimDD, TrautmannME, BrodowsRG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med, 2007; 146:477–485.
14.
BuseJB, KlonoffDC, NielsenLL, GuanX, BowlusCL, HolcombeJH, MaggsDG, WintleME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther, 2007; 29:139–153.
15.
RendellM. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 2004; 64:1339–1358.
16.
RydénL, StandlE, BartnikM, Van den BergheG, BetteridgeJ, de BoerMJ, CosentinoF, JönssonB, LaaksoM, MalmbergK, PrioriS, OstergrenJ, TuomilehtoJ, ThrainsdottirI, VanhorebeekI, Stramba-BadialeM, LindgrenP, QiaoQ, PrioriSG, BlancJJ, BudajA, CammJ, DeanV, DeckersJ, DicksteinK, LekakisJ, McGregorK, MetraM, MoraisJ, OsterspeyA, TamargoJ, ZamoranoJL, DeckersJW, BertrandM, CharbonnelB, ErdmannE, FerranniniE, FlyvbjergA, GohlkeH, JuanateyJR, GrahamI, MonteiroPF, ParhoferK, PyöräläK, RazI, SchernthanerG, VolpeM, WoodD. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD): Guidelines on diabetes, pre-diabetes, cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)Eur Heart J, 2007; 28:88–136.
17.
Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol, 2006; 26:2186–2191.
18.
BunnHF, GabbayKH, GallopPM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science, 1978; 200:21–27.
19.
European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med, 1999; 16:716–730.
20.
HedingLG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia, 1972; 8:260–266.
21.
MatthewsDR, HoskerJP, RudenskiAS, NaylorBA, TreacherDF, TurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
22.
WallaceTM, LevyJC, MatthewsDR. Use and abuse of HOMA modeling. Diabetes Care, 2004; 27:1487–1495.
23.
HoussaP, DinensenB, DebergM, FrankBH, Van SchravendijkC, Sodoyez-GoffauxF, SodoyezJ-C. First direct assay for intact human proinsulin. Clin Chem, 1998; 44:1514–1519.
24.
YannakouliaM, YiannakourisN, BluherS, MatalasAL, Klimis-ZacasD, MantzorosCS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concen-trations in healthy humans. J Clin Endocrinol Metab, 2003; 88:1730–1736.
25.
TakebayashiK, SuetsuguM, WakabayashiS, AsoY, InumaiT. Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab, 2007; 92:2712–2719.
26.
RifaiN, TracyRP, RidkerPM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem, 1999; 45:2136–2141.
27.
WinerBJ. Statistical Principles in Experimental Design, 2nd. New York: McGraw-Hill, 1971.
28.
HeineRJ, Van GaalLF, JohnsD, MihmMJ, WidelMH, BrodowsRG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med, 2005; 143:559–569.
29.
BarnettAH, BurgerJ, JohnsD, BrodowsR, KendallDM, RobertsA, TrautmannME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther, 2007; 29:2333–2348.
30.
NauckMA, DuranS, KimD, JohnsD, NorthrupJ, FestaA, BrodowsR, TrautmannM. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia, 2007; 50:259–267.
31.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:837–853.
32.
BarnettA, AllsworthJ, JamesonK, MannR. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin, 2007; 23:1493–1507.
33.
MaggioCA, Pi-SunyerFX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am, 2003; 32:805–822.
34.
BrayGA. Medical consequences ofobesity. J Clin Endocrinol Metab, 2004; 89:2583–2589.
35.
Yki-JärvinenH, WesterbackaJ. The fatty liver and insulin resistance. Curr Mol Med, 2005; 5:287–295.
36.
SongY, MansonJE, TinkerL, HowardBV, KullerLH, NathanL, RifaiN, LiuS. Insulin sensitivity and insulin secretion determined by homeostasis model assessment (HOMA) and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative observational study. Diabetes Care, 2007; 30:1747–1752.
37.
LiYB, ZhuDL, TianHM, ShiLX, LuoZJ, YanL, ZengLY, ZhouZG, YangLY, LiuJ, LiM, WengJP. Characteristics of dysfunction of islet beta-cell in newly diagnosed type 2 diabetic patients [in Chinese]Zhonghua Yi Xue Za Zhi, 2006; 86:2537–2541.
38.
PfütznerA, PfütznerAH, LarbigM, ForstT. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther, 2004; 6:405–412.
39.
MorettoTJ, MiltonDR, RidgeTD, MacConellLA, OkersonT, WolkaAM, BrodowsRG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2008; 30:1448–1460.
40.
SteppanCM, BaileyST, BhatS, BrownEJ, BanerjeeRR, WrightCM, PatelHR, AhimaRS, LazarMA. The hormone resistin links obesity to diabetes. Nature, 2001; 409:307–312.
41.
SatohH, NguyenMT, MilesPD, ImamuraT, UsuiI, OlefskyJM. Adenovirus-mediated chronic ‘hyper-resistinemia’ leads to in vivo insulin resistance in normal rats. J Clin Invest, 2004; 114:224–231.
42.
RangwalaSM, RichAS, RhoadesB, ShapiroJS, ObiciS, RossettiL, LazarMA. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 2004; 53:1937–1941.
43.
ReillyMP, LehrkeM, WolfeM, RohatgiA, LazarMA, RaderDJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 2005; 111:932–939.
44.
ChoYM, YounBS, LeeH, LeeN, MinSS, KwakSH, LeeHK, ParkKS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care, 2006; 29:2457–2461.
